About Index Trending news
Lists
Pricing
Jounce Therapeutics

Jounce Therapeutics

Jounce Therapeutics

Jounce Therapeutics is developing cancer immune-therapies to harness the immunesystem to attack cancerous cells and tumors.

Elsewhere

Alexa global traffic share

Latest funding
IPO
$102,000,000
Venture capital (Series B)
$56,000,000
Employees

Team size

50+
Locations
HQ
$102,000,000 IPO
Xconomy

Jounce Gets $102M As Biotech IPOs Gain Steam in ’17

Stock markets Earnings
$56,000,000 Venture capital (Series B)
VentureWire

The Daily Startup: Jounce Therapeutics Raises $56M as Immunotherapy Stays Hot

Funding